Literature DB >> 7526850

Human erythrocyte ankyrin, a cytoskeleton component, generates the p57 membrane proteinase which cleaves C3, the third component of complement.

J Hermann1, M Barel, R Frade.   

Abstract

Human erythrocytes express a p57 membrane serine proteinase which cleaves C3, the third component of complement. Amino acid analysis of the first 20 N-terminal residues of the purified p57 proteinase demonstrated 100% homology with residues 910-929 of erythrocyte ankyrin, a sequence localized in its Mr = 62 kDa fragment. Thus, we analyzed whether ankyrin could generate the p57 C3-cleaving activity. We demonstrate herein that: 1) anti-ankyrin antibodies react with purified p57 proteinase; 2) anti-p57 proteinase antibodies react with purified ankyrin but not with spectrin, another cytoskeleton component; 3) while purified ankyrin did not carry any detectable proteinase activity, limited proteolysis of ankyrin by immobilized chymotrypsin generated this C3-cleaving serine proteinase. Spectrin did not generate any C3-cleaving activity. This is the first demonstration that erythrocyte ankyrin could generate a proteinase activity, which in addition, cleaves specifically human C3.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7526850     DOI: 10.1006/bbrc.1994.2481

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  Identification on melanoma cells of p39, a cysteine proteinase that cleaves C3, the third component of complement: amino-acid-sequence identities with procathepsin L.

Authors:  D Jean; J Hermann; F Rodrigues-Lima; M Barel; M Balbo; R Frade
Journal:  Biochem J       Date:  1995-12-15       Impact factor: 3.857

2.  The proteins cleaved by endogenous tryptic proteases in normal EDTA plasma by C18 collection of peptides for liquid chromatography micro electrospray ionization and tandem mass spectrometry.

Authors:  Jaimie Dufresne; Angelique Florentinus-Mefailoski; Juliet Ajambo; Ammara Ferwa; Peter Bowden; John Marshall
Journal:  Clin Proteomics       Date:  2017-12-02       Impact factor: 3.988

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.